RecruitingPhase 3NCT04817618

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Studying C3 glomerulopathy

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals
Novartis Pharmaceuticals
Intervention: Placebo(drug)
Enrollment: 98 enrolled
Eligibility: 12-60 years · All sexes
Timeline: 2021 – 2027

Study locations (30)

Childrens Hospital Colorado, Aurora, Colorado, United States
Nicklaus Childrens Hospital, Miami, Florida, United States
Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
IN University School of Med, Indianapolis, Indiana, United States
University of Iowa Health Care, Iowa City, Iowa, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States
Hackensack Uni Medical Center, Hackensack, New Jersey, United States
Albany Medical Center, Albany, New York, United States
Col Uni Med Center New York Presby, New York, New York, United States
Baylor Scott and White Research, Temple, Texas, United States
University of Wisconsin, Madison, Wisconsin, United States
Novartis Investigative Site, Córdoba, Córdoba Province, Argentina
Novartis Investigative Site, Buenos Aires, Argentina
Novartis Investigative Site, CABA, Argentina
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04817618 on ClinicalTrials.gov

Other trials for C3 glomerulopathy

Additional recruiting or active studies for the same condition.

See all trials for C3 glomerulopathy →

← Back to all trials